Attached files
| file | filename |
|---|---|
| EX-10.34 - EX-10.34 - Intra-Cellular Therapies, Inc. | d863619dex1034.htm |
| EX-32.1 - EX-32.1 - Intra-Cellular Therapies, Inc. | d863619dex321.htm |
| EX-31.2 - EX-31.2 - Intra-Cellular Therapies, Inc. | d863619dex312.htm |
| EX-31.1 - EX-31.1 - Intra-Cellular Therapies, Inc. | d863619dex311.htm |
| EX-10.33 - EX-10.33 - Intra-Cellular Therapies, Inc. | d863619dex1033.htm |
| EX-10.32 - EX-10.32 - Intra-Cellular Therapies, Inc. | d863619dex1032.htm |
| EX-10.28 - EX-10.28 - Intra-Cellular Therapies, Inc. | d863619dex1028.htm |
| EX-4.2 - EX-4.2 - Intra-Cellular Therapies, Inc. | d863619dex42.htm |
| 10-K - FORM 10-K - Intra-Cellular Therapies, Inc. | d863619d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-235817) of Intra-Cellular Therapies, Inc.,
(2) Registration Statement (Form S-3 No. 333-233537) of Intra-Cellular Therapies, Inc.,
(3) Registration Statement (Form S-8 No. 333-225799) pertaining to the Intra-Cellular Therapies, Inc. 2018 Equity Incentive Plan of Intra-Cellular Therapies, Inc.,
(4) Registration Statement (Form S-8 No. 333-205070) pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.,
(5) Registration Statement (Post-Effective Amendment No. 3 to Form S-1 on Form S-3 No. 333-191238) of Intra-Cellular Therapies, Inc., and
(6) Registration Statement (Form S-8 No. 333-193310) pertaining to the ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. 2013 Equity Incentive Plan of Intra-Cellular Therapies, Inc.;
of our reports dated March 2, 2020, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this Annual Report (Form 10-K) of Intra-Cellular Therapies, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Baltimore, Maryland
March 2, 2020